Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Authors' conclusion
In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss and improvements in anthropometric measurements versus placebo. Weight loss was sustained over 4 years.
Study context
- Population
- Adults with preexisting CVD and overweight or obesity, without diabetes
- Participants
- 17,604 adults
- Comparison
- Semaglutide vs placebo
- Primary endpoint
- Weight and anthropometric outcomes, safety and tolerability by baseline BMI
- Follow-up
- 208 weeks
Methodological detailsprespecified analysis
- Prespecified analysis
Primary result
As reported in the abstract
Weight, waist circumference, waist-to-height ratio
| Group | Weight | Waist circumference | Waist-to-height ratio |
|---|---|---|---|
| Semaglutide | −10.2% | −7.7 cm | −6.9% |
| Placebo | −1.5% | −1.3 cm | −1.0% |
Weight
Semaglutide−10.2%
Placebo−1.5%
Waist circumference
Semaglutide−7.7 cm
Placebo−1.3 cm
Waist-to-height ratio
Semaglutide−6.9%
Placebo−1.0%
- Semaglutide vs Placebo: P < 0.0001 — for all comparisons
Further findings
Weight loss trajectory
- With semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years
- Clinically meaningful weight loss in both sexes and all races, body sizes and regions
Safety
| Outcome | Semaglutide | Placebo |
|---|---|---|
| Serious adverse events (events per 100 years of observation), by BMI categoryFewer serious adverse events with semaglutide | ||
| BMI <30 | 43.23 | 50.48 |
| BMI 30 to <35 | 43.54 | 49.66 |
| BMI 35 to <40 | 51.07 | 52.73 |
| BMI ≥40 | 47.06 | 60.85 |
Trial product discontinuation
- Increased rates with semaglutide; discontinuations increased as body mass index (BMI) class decreased
Original publication
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. Published 13 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →